

NA Thyroid Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 217 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The North America thyroid cancer diagnostics market is projected to register a substantial CAGR of 6.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation:

North America Thyroid Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, Others), Cancer Type (Papillary Carcinoma, Follicular Carcinoma, Others), Stages (Stage I, Stage II, Stage III, Stage IV), Age Group (30-65, 65 and above, 21-29, Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the North America thyroid cancer diagnostics market are:

- Rising incidence and prevalence of thyroid nodules & cancer
- Rising thyroid cancer diagnostic tests rise in product approvals
- Rising awareness towards thyroid cancer

Market Players:

Some major companies which are dealing in the North America thyroid cancer diagnostics market are listed below:

- Canon Inc.
- FUJIFILM Holdings Corporation
- F. Hoffmann-La Roche Ltd
- Quest Diagnostics Incorporated
- Illumina
- Koninklijke Philips N.V.
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- Abbott
- General Electric Company

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- QIAGEN
- DIASORIN S.P.A.
- Merck KGaA
- Hologic
- Myriad Genetics Inc.
- BIOMERIEUX
- FONAR Corp.
- Time Medical Holding.
- MinFound Medical Systems Co., Ltd

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	46
1.1 OBJECTIVES OF THE STUDY	46
1.2 MARKET DEFINITION	46
1.3 OVERVIEW OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET	46
1.4 LIMITATIONS	48
1.5 MARKETS COVERED	48
2 MARKET SEGMENTATION	51
2.1 MARKETS COVERED	51
2.2 GEOGRAPHICAL SCOPE	52
2.3 YEARS CONSIDERED FOR THE STUDY	53
2.4 CURRENCY AND PRICING	53
2.5 DBMR TRIPOD DATA VALIDATION MODEL	54
2.6 MULTIVARIATE MODELLING	57
2.7 PRODUCT TYPE LIFELINE CURVE	57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	58
2.9 DBMR MARKET POSITION GRID	59
2.10 MARKET TESTING TYPE COVERAGE GRID	61
2.11 VENDOR SHARE ANALYSIS	62
2.12 SECONDARY SOURCES	63
2.13 ASSUMPTIONS	63
3 EXECUTIVE SUMMARY	64
4 PREMIUM INSIGHTS	67
4.1 PESTEL ANALYSIS	68
4.2 PORTER'S FIVE FORCES	69
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS	70
5 EPIDEMIOLOGY	71
6 REGULATORY FRAMEWORK OF THE NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET	72
6.1 REGULATORY SCENARIO IN THE U.S.	72
6.2 REGULATORY SCENARIO IN AUSTRALIA	73
6.3 REGULATORY SCENARIO IN JAPAN	73
6.4 REGULATORY SCENARIO IN CHINA	73
7 MARKET OVERVIEW	74
7.1 DRIVERS	76

7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER	76
7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS	76
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS	77
7.1.4 RISING AWARENESS TOWARDS THYROID CANCER	77
7.2 RESTRAINTS	78
7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE	78
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS	79
7.3 OPPORTUNITIES	79
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT	79
7.3.2 RISING OBESE POPULATION	80
7.4 CHALLENGES	80
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS	80
8 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE	82
8.1 OVERVIEW	83
8.2 INSTRUMENTS	86
8.2.1 PATHOLOGY BASED INSTRUMENTS	87
8.2.1.1 PCR INSTRUMENTS	87
8.2.1.2 SLIDE STAINING SYSTEMS	87
8.2.1.3 TISSUE PROCESSING SYSTEMS	87
8.2.1.4 CELL PROCESSORS	88
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS	88
8.2.2 IMAGING INSTRUMENTS	88
8.2.2.1 ULTRASOUND SYSTEMS	88
8.2.2.2 CT SYSTEMS	88
8.2.2.3 MRI SYSTEMS	88
8.2.2.4 OTHERS	88
8.2.3 BIOPSY INSTRUMENTS	89
8.2.3.1 NEEDLE BIOPSY	89
8.2.3.2 ENDOSCOPIC BIOPSY	89
8.2.3.3 CORE BIOPSY	89
8.2.3.4 OTHERS	89
8.2.4 OTHERS	89
8.3 CONSUMABLES & ACCESSORIES	90
8.3.1 KITS	91
8.3.1.1 PCR KITS	91
8.3.1.2 DNA POLYMERASE KITS	91
8.3.1.3 NUCLEIC ACID ISOLATION KITS	91
8.3.1.4 OTHERS	91
8.3.2 REAGENTS	92
8.3.2.1 ASSAYS	92
8.3.2.2 BUFFERS	92
8.3.2.3 PRIMERS	92
8.3.2.4 OTHERS	92
8.3.3 PROBES	92
8.3.4 OTHER CONSUMABLES	92

9 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 93

9.1 OVERVIEW 94

9.2 IMAGING TEST 97

9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 98

9.2.2 MRI 98

9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 98

9.2.4 OTHERS 98

9.3 BLOOD TEST 99

9.3.1 BLOOD CHEMISTRY TESTS 100

9.3.2 COMPLETE BLOOD COUNT (CBC) 100

9.3.3 OTHERS 100

9.4 BIOPSY 100

9.4.1 NEEDLE BIOPSY 101

9.4.2 BRONCHOSCOPY BIOPSY 101

9.4.3 CORE BIOPSY 101

9.4.4 OTHERS 101

9.5 OTHERS 102

10 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 103

10.1 OVERVIEW 104

10.2 PAPILLARY CARCINOMA 107

10.3 FOLLICULAR CARCINOMA 108

10.4 OTHERS 109

11 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 110

11.1 OVERVIEW 111

11.2 STAGE I 114

11.3 STAGE II 115

11.4 STAGE III 116

11.5 STAGE IV 117

12 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 118

12.1 OVERVIEW 119

12.2 30-65 122

12.3 65 AND ABOVE 123

12.4 21-29 124

12.5 BELOW 21 125

13 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER 126

13.1 OVERVIEW 127

13.2 HOSPITALS 130

13.3 ASSOCIATED LABS 131

13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131

13.5 DIAGNOSTIC IMAGING CENTERS 132

13.6 CANCER RESEARCH INSTITUTES 133

13.7 OTHERS 134

14 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135

14.1 OVERVIEW 136

14.2 DIRECT TENDER 139

14.3 RETAIL SALES 140

15 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET, BY REGION 141

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.1 NORTH AMERICA 142
15.1.1 U.S. 152
15.1.2 CANADA 157
15.1.3 MEXICO 162
16 NORTH AMERICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 167
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 167
17 SWOT ANALYSIS 168
18 COMPANY PROFILE 169
18.1 CANON INC. 169
18.1.1 COMPANY SNAPSHOT 169
18.1.2 COMPANY SHARE ANALYSIS 169
18.1.3 PRODUCT PORTFOLIO 170
18.1.4 RECENT DEVELOPMENTS 170
18.2 FUJIFILM CORPORATION 171
18.2.1 COMPANY SNAPSHOT 171
18.2.2 REVENUE ANALYSIS 171
18.2.3 COMPANY SHARE ANALYSIS 172
18.2.4 PRODUCT PORTFOLIO 172
18.2.5 RECENT DEVELOPMENT 172
18.3 F. HOFFMANN-LA ROCHE LTD 173
18.3.1 COMPANY SNAPSHOT 173
18.3.2 REVENUE ANALYSIS 173
18.3.3 COMPANY SHARE ANALYSIS 174
18.3.4 PRODUCT PORTFOLIO 174
18.3.5 RECENT DEVELOPMENT 174
18.4 QUEST DIAGNOSTICS INCORPORATED 175
18.4.1 COMPANY SNAPSHOT 175
18.4.2 REVENUE ANALYSIS 175
18.4.3 COMPANY SHARE ANALYSIS 176
18.4.4 PRODUCT PORTFOLIO 176
18.4.5 RECENT DEVELOPMENTS 176
18.5 ILLUMINA, INC. 178
18.5.1 COMPANY SNAPSHOT 178
18.5.2 REVENUE ANALYSIS 178
18.5.3 COMPANY SHARE ANALYSIS 179
18.5.4 PRODUCT PORTFOLIO 179
18.5.5 RECENT DEVELOPMENT 179
18.6 ABBOTT 180
18.6.1 COMPANY SNAPSHOT 180
18.6.2 REVENUE ANALYSIS 180
18.6.3 PRODUCT PORTFOLIO 181
18.6.4 RECENT DEVELOPMENT 181
18.7 BD 182
18.7.1 COMPANY SNAPSHOT 182
18.7.2 REVENUE ANALYSIS 182
18.7.3 PRODUCT PORTFOLIO 183
18.7.4 RECENT DEVELOPMENT 183

18.8 BEIJING O&D BIOTECH CO., LTD.	184
18.8.1 COMPANY SNAPSHOT	184
18.8.2 PRODUCT PORTFOLIO	184
18.8.3 RECENT DEVELOPMENTS	184
18.9 BIOMERIEUX SA	185
18.9.1 COMPANY SNAPSHOT	185
18.9.2 REVENUE ANALYSIS	185
18.9.3 PRODUCT PORTFOLIO	186
18.9.4 RECENT DEVELOPMENTS	186
18.10 DIASORIN S.P.A.	187
18.10.1 COMPANY SNAPSHOT	187
18.10.2 REVENUE ANALYSIS	187
18.10.3 PRODUCT PORTFOLIO	188
18.10.4 RECENT DEVELOPMENT	188
18.11 FONAR CORP.	189
18.11.1 COMPANY SNAPSHOT	189
18.11.2 REVENUE ANALYSIS	189
18.11.3 PRODUCT PORTFOLIO	190
18.11.4 RECENT DEVELOPMENTS	190
18.12 GENERAL ELECTRIC	191
18.12.1 COMPANY SNAPSHOT	191
18.12.2 REVENUE ANALYSIS	191
18.12.3 PRODUCT PORTFOLIO	192
18.12.4 RECENT DEVELOPMENTS	192
18.13 HOLOGIC INC.	193
18.13.1 COMPANY SNAPSHOT	193
18.13.2 REVENUE ANALYSIS	193
18.13.3 PRODUCT PORTFOLIO	194
18.13.4 RECENT DEVELOPMENT	194
18.14 KONINKLIJKE PHILIPS N.V.	195
18.14.1 COMPANY SNAPSHOT	195
18.14.2 REVENUE ANALYSIS	195
18.14.3 PRODUCT PORTFOLIO	196
18.14.4 RECENT DEVELOPMENT	196
18.15 MERCK KGAA.	197
18.15.1 COMPANY SNAPSHOT	197
18.15.2 REVENUE ANALYSIS	197
18.15.3 PRODUCT PORTFOLIO	198
18.15.4 RECENT DEVELOPMENT	198
18.16 MEDONICA CO. LTD	199
18.16.1 COMPANY SNAPSHOT	199
18.16.2 PRODUCT PORTFOLIO	199
18.16.3 RECENT DEVELOPMENT	199
18.17 MINFOUND MEDICAL SYSTEMS CO. LTD	200
18.17.1 COMPANY SNAPSHOT	200
18.17.2 PRODUCT PORTFOLIO	200
18.17.3 RECENT DEVELOPMENTS	201

18.18 MYRIAD GENETICS, INC.	202
18.18.1 COMPANY SNAPSHOT	202
18.18.2 REVENUE ANALYSIS	202
18.18.3 PRODUCT PORTFOLIO	203
18.18.4 RECENT DEVELOPMENTS	203
18.19 PLEXBIO.	204
18.19.1 COMPANY SNAPSHOT	204
18.19.2 PRODUCT PORTFOLIO	204
18.19.3 RECENT DEVELOPMENTS	204
18.20 QIAGEN	205
18.20.1 COMPANY SNAPSHOT	205
18.20.2 REVENUE ANALYSIS	205
18.20.3 PRODUCT PORTFOLIO	206
18.20.4 RECENT DEVELOPMENT	206
18.21 STERNMED GMBH	207
18.21.1 COMPANY SNAPSHOT	207
18.21.2 PRODUCT PORTFOLIO	207
18.21.3 RECENT DEVELOPMENTS	207
18.22 SIEMENS HEALTHCARE GMBH	208
18.22.1 COMPANY SNAPSHOT	208
18.22.2 REVENUE ANALYSIS	208
18.22.3 PRODUCT PORTFOLIO	209
18.22.4 RECENT DEVELOPMENT	209
18.23 TIME MEDICAL HOLDING.	210
18.23.1 COMPANY SNAPSHOT	210
18.23.2 PRODUCT PORTFOLIO	210
18.23.3 RECENT DEVELOPMENT	210
18.24 THERMO FISHER SCIENTIFIC INC.	211
18.24.1 COMPANY SNAPSHOT	211
18.24.2 REVENUE ANALYSIS	211
18.24.3 PRODUCT PORTFOLIO	212
18.24.4 RECENT DEVELOPMENT	212
19 QUESTIONNAIRE	213

NA Thyroid Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 217 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-08"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com